8月15日，东星医疗今日收盘27.5元，上涨1.48%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到30.75倍，总市值27.55亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.58倍，行业中值39.97倍，东星医疗排 名第59位。 江苏东星智慧医疗科技股份有限公司的主营业务是外科手术医疗器械的研发、生产和销售。公司的主要 产品是腔镜吻合器、开放式吻合器、吻合器零部件、电动液压手术床、手术无影灯、吊塔吊桥、产床。 股东方面，截至2025年7月31日，东星医疗股东户数11138户，较上次减少7户，户均持股市值35.28万 元，户均持股数量2.76万股。 最新一期业绩显示，2025年一季报，公司实现营业收入7818.65万元，同比-14.84%；净利润1206.40万 元，同比-39.35%，销售毛利率44.40%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13东星医疗30.7528.281.2227.55亿行业平均 56.5852.305.00119.53亿行业中值39.9739.072.9157.03亿1九安医疗11.3611.490.89191.70亿2英科 ...

Company Overview - Dongxing Medical closed at 26.88 yuan, up 1.28%, with a rolling PE ratio of 30.05, marking a new low in 39 days, and a total market capitalization of 2.693 billion yuan [1] - The company ranks 58th in the medical device industry, which has an average PE ratio of 55.41 and a median of 37.94 [1] Shareholder Information - As of July 18, 2025, Dongxing Medical had 11,145 shareholders, a decrease of 347 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Dongxing Medical specializes in the research, production, and sales of surgical medical devices, with key products including laparoscopic staplers, open staplers, stapler components, electric hydraulic surgical tables, shadowless surgical lights, and delivery beds [1] Financial Performance - In the first quarter of 2025, the company reported revenue of 78.1865 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.064 million yuan, down 39.35%, with a gross margin of 44.40% [1] Industry Comparison - The PE ratios for Dongxing Medical and its peers are as follows: Dongxing Medical at 30.05, with the industry average at 55.41 and the median at 37.94 [2]

Company Overview - Dongxing Medical closed at 26.2 yuan on July 16, with a 2.34% increase, and a rolling PE ratio of 29.29, marking a new low in 27 days, with a total market value of 2.625 billion yuan [1] - The company's main business includes the research, production, and sales of surgical medical devices, with key products such as endoscopic staplers, open staplers, stapler components, electric hydraulic surgical tables, shadowless surgical lights, and delivery beds [1] Financial Performance - In the latest quarterly report for Q1 2025, Dongxing Medical reported operating revenue of 78.1865 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.064 million yuan, down 39.35%, with a gross profit margin of 44.40% [1] Industry Comparison - The average PE ratio for the medical device industry is 51.87, with a median of 37.48, placing Dongxing Medical at the 62nd position in the industry ranking [1] - The company's static PE ratio is 26.94, and its price-to-book ratio is 1.16 [2] - Other companies in the industry have varying PE ratios, with the highest being 19.04 for Antu Biology and the lowest at 10.85 for Jiuan Medical [2] Capital Flow - On July 16, Dongxing Medical experienced a net inflow of main funds amounting to 5.7309 million yuan, although it has seen a total outflow of 9.1392 million yuan over the past five days [1]

Group 1 - The core viewpoint of the articles highlights Dongxing Medical's current stock performance, with a closing price of 25.93 yuan, an increase of 1.89%, and a rolling PE ratio of 28.99, marking a new low in 18 days [1] - Dongxing Medical's total market capitalization is reported at 25.97 billion yuan, with the average PE ratio in the medical device industry at 51.42, and the median at 37.44, placing Dongxing Medical at the 65th position in the industry ranking [1][2] - As of June 30, 2025, Dongxing Medical has 11,381 shareholders, a decrease of 123 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Group 2 - Dongxing Medical specializes in the research, production, and sales of surgical medical devices, with key products including endoscopic staplers, open staplers, stapler components, electric hydraulic surgical tables, shadowless surgical lights, and delivery beds [1] - The latest quarterly report for Q1 2025 shows Dongxing Medical achieved operating revenue of 78.19 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.06 million yuan, down 39.35%, with a gross profit margin of 44.40% [1]

Company Overview - Dongxing Medical closed at 25.43 yuan on July 3, with a 4.22% increase, resulting in a rolling PE ratio of 28.43, the lowest in 13 days, and a total market capitalization of 2.547 billion yuan [1] - The company ranks 62nd in the medical device industry, which has an average PE of 51.48 and a median PE of 36.88 [1] Financial Performance - For Q1 2025, Dongxing Medical reported revenue of 78.1865 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.064 million yuan, down 39.35% year-on-year, with a gross margin of 44.40% [1] Capital Flow - On July 3, Dongxing Medical experienced a net inflow of 7.9205 million yuan from main funds, although it has seen a total outflow of 9.666 million yuan over the past five days [1] Industry Comparison - The medical device industry has an average PE of 51.48 and a median PE of 36.88, indicating that Dongxing Medical's valuation is significantly lower than the industry average [2]

Group 1 - The core viewpoint of the articles indicates that Dongxing Medical's stock is currently underperforming compared to its industry peers, with a PE ratio of 27.35, significantly lower than the industry average of 49.45 [1][2] - Dongxing Medical's market capitalization stands at 2.45 billion yuan, ranking 62nd in the medical device industry based on PE ratio [1][2] - The company reported a revenue of 78.19 million yuan for Q1 2025, reflecting a year-on-year decline of 14.84%, and a net profit of 12.06 million yuan, down 39.35% year-on-year, with a gross margin of 44.40% [1] Group 2 - The medical device industry has an average PE ratio of 49.45 and a median of 35.92, indicating a generally higher valuation compared to Dongxing Medical [2] - The main products of Dongxing Medical include surgical instruments such as endoscopic staplers, open staplers, and electric hydraulic surgical beds [1] - In terms of capital flow, Dongxing Medical experienced a net outflow of 851,900 yuan on June 26, but had a total inflow of 4.25 million yuan over the past five days [1]

Company Overview - Dongxing Medical closed at 24.09 yuan on May 20, with an increase of 1.52%, resulting in a rolling PE ratio of 26.93 times and a total market value of 2.413 billion yuan [1] - The company ranks 58th in the medical device industry, which has an average PE ratio of 49.51 times and a median of 36.17 times [1] Financial Performance - For Q1 2025, Dongxing Medical reported operating revenue of 78.1865 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.064 million yuan, down 39.35% year-on-year, with a gross profit margin of 44.40% [1] Capital Flow - On May 20, the net inflow of main funds into Dongxing Medical was 1.2033 million yuan, with a total inflow of 11.8631 million yuan over the past five days [1]

Company Overview - Dongxing Medical's closing price on May 14 was 24.49 yuan, an increase of 2.08%, with a rolling PE ratio of 27.38, marking a new low in 37 days, and a total market capitalization of 2.453 billion yuan [1] - The company specializes in the research, production, and sales of surgical medical devices, with main products including endoscopic staplers, open staplers, stapler components, electric hydraulic surgical tables, shadowless surgical lights, and delivery beds [1] Financial Performance - In the first quarter of 2025, Dongxing Medical reported operating revenue of 78.1865 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.064 million yuan, down 39.35% year-on-year, with a gross profit margin of 44.40% [1] Shareholder Information - As of May 9, 2025, Dongxing Medical had 10,593 shareholders, a decrease of 35 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 49.84, with a median of 36.65, placing Dongxing Medical at the 61st position in the industry ranking [2]

Financial Performance - In 2024, the company achieved total revenue of 36.726 billion CNY, a year-on-year increase of 5.14% [2] - The net profit attributable to shareholders was 11.668 billion CNY, up 0.74% year-on-year; excluding financial expenses, the net profit growth was 4.36% [2] - Operating cash flow reached 12.432 billion CNY, reflecting a year-on-year increase of 12.38% [2] - For Q1 2025, total revenue was 8.237 billion CNY, a decline of 12.12% compared to the same period last year, with net profit down 16.81% [9] Dividend Distribution - The company plans to distribute 679 million CNY (including tax) as dividends for 2024, with a cumulative cash dividend of 7.602 billion CNY, representing a payout ratio of 65.15% [3] - A proposal for a mid-year dividend of 1.71 billion CNY (including tax) for 2025 is also in place, pending shareholder approval [3] Market Performance International Market - The international market grew by 21.28% in 2024, with the Asia-Pacific region seeing nearly 40% growth driven by countries like Australia, Thailand, and India [4] - International revenue accounted for approximately 45% of total revenue, with high-potential segments like minimally invasive surgery and cardiovascular care nearing 10% of international income [4] Domestic Market - The domestic market experienced a decline of 5.10% due to sluggish hospital equipment procurement and the impact of DRG 2.0 [4] - A recovery is anticipated in Q3 2025 as local fiscal pressures ease and medical equipment projects are initiated [4] Product Line Performance In Vitro Diagnostics (IVD) - The IVD segment grew by 10.82% in 2024, with international IVD growth exceeding 30% [5] - IVD revenue now constitutes 37.48% of total company revenue, surpassing the life information and support segment [5] Medical Imaging - The medical imaging segment grew by 6.60%, with international growth over 15% [7] - The launch of the high-end Resona A20 ultrasound is expected to enhance market presence [7] Life Information and Support - This segment saw a decline of 11.11%, although international growth was in double digits [8] - The company maintains a leading market share in domestic monitoring and respiratory devices despite challenges [8] Research and Development - R&D investment for 2024 was 4.008 billion CNY, accounting for 10.91% of revenue, while Q1 2025 saw 847 million CNY in R&D, representing 10.28% of revenue [11] - New product launches include advanced systems in life information and support, IVD, and medical imaging [12][13] Sustainability Efforts - The company received an AA rating from MSCI ESG and was included in the S&P Global Sustainable Development Yearbook [14] - Carbon emissions intensity decreased by 11.6% compared to 2021, with ongoing projects contributing to sustainability goals [15] Future Outlook - The company anticipates a significant recovery in domestic revenue starting Q3 2025, driven by the resumption of medical equipment projects [10] - Long-term growth strategies focus on digitalization, internationalization, and enhancing the supply chain to adapt to changing market conditions [24][25]

东星医疗收盘上涨1.46%，滚动市盈率25.82倍，总 市值23.60亿元 3月26日，东星医疗今日收盘23.56元，上涨1.46%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到25.82倍，总市值23.60亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)58东星医疗25.8224.281.0723.60亿行业平均 45.1449.524.84107.93亿行业中值31.9931.002.4848.44亿1硕世生物-1949.53-1949.531.2340.28亿2诺唯 赞-562.38-562.382.4395.62亿3利德曼-363.03174.161.5426.71亿4博晖创新-300.71-185.143.3146.15亿5康泰 医学-292.3334.302.9956.86亿6华大基因-221.13241.882.29224.71亿7奥精医疗-121.20-121.201.5421.96亿8 睿昂基因-82.72-82.721.2911.96亿9华大智造-55.10-55.104.14330.13亿10中红医疗-54.40-37.010.8648.44亿 11天智航- ...